MAPK
Catalog No.
Product Name
Application
Product Information
Citations
-
p38 MAPK Inhibitor
p38 MAPK-IN-2 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). This compound effectively attenuates p38 MAPK signaling, leading to decreased phosphorylation of downstream targets involved in inflammatory responses. It is valuable for researchers studying cellular stress responses, cytokine signaling, and potential therapeutic effects in various inflammatory diseases and cancer. -
p38 MAPK Inhibitor
2-Phenylacetamide is a potent inhibitor of the p38 MAPK signaling pathway. This compound demonstrates significant anti-inflammatory, antioxidant, anti-hypertensive, and anti-fibrotic properties, making it a valuable tool for investigating various biological processes. Additionally, 2-Phenylacetamide is orally active, facilitating its use in in vivo research applications. -
JNK Inhibitor
JNK-9L is an ATP-competitive inhibitor targeting c-Jun N-terminal kinases (JNK1 and JNK3), exhibiting IC50 values of 0.099 and 0.148 μM, respectively. This compound effectively inhibits c-jun phosphorylation and reduces reactive oxygen species (ROS) generation induced by Streptozotocin with an IC50 of 0.8 nM. JNK-9L is particularly relevant for research into neurodegenerative diseases, including Parkinson’s disease, facilitating investigations into the therapeutic modulation of JNK pathways. -
MEK1/2 Inhibitor
U0126 is a selective inhibitor of MEK1 and MEK2, functioning through a non-ATP competitive mechanism. It demonstrates potent biological activity with IC50 values of 72 nM and 58 nM for MEK1 and MEK2, respectively. U0126 is utilized in research to investigate autophagy and mitophagy processes, providing insights into cellular signaling pathways and potential therapeutic targets in cancer and other diseases. -
p38 MAPK Inhibitor
p38 MAPK-IN-1 is a selective inhibitor of p38 MAPK, exhibiting an IC50 of 68 nM. This compound demonstrates sustained plasma levels, low clearance, and favorable bioavailability, making it an effective tool for biological research. p38 MAPK-IN-1 is primarily utilized in studies investigating inflammatory responses, apoptosis, and various disease states involving p38 MAPK signaling pathways. -
p38 MAPK Inhibitor
Doramapimod hydrochloride is a selective inhibitor of p38 MAPK, a key regulator in inflammatory responses. This compound effectively attenuates the production of pro-inflammatory cytokines, including TNF-α and IL-1β, in response to LPS, LTA, and PGN stimulation. Its potent anti-inflammatory properties make Doramapimod hydrochloride valuable for researching various autoimmune diseases and inflammatory pathways. -
MEK Inhibitor
Zapnometinib is a potent MEK inhibitor with an IC50 of 5.7 nM, acting primarily on the MAPK/ERK signaling pathway. This compound displays antiviral activity against the influenza virus and possesses antibacterial properties, making it a valuable tool for research applications in virology and microbiology. Its efficacy in inhibiting MEK highlights its potential for studies related to cancer and inflammatory diseases. -
P38 MAPK Inhibitor
2-Oleoxyphenethyl phosphocholin is an inhibitor of the p38 MAPK pathway, which plays a critical role in cellular stress responses and inflammatory processes. This compound exhibits significant anticancer activity, potentially through its interaction with the lipid-binding pocket of p38 MAPK. Its broad-spectrum anti-tumor properties make 2-Oleoxyphenethyl phosphocholin a valuable tool for research in cancer biology and therapeutic development. -
p38α MAPK Inhibitor
p38-α MAPK-IN-4 is a selective inhibitor of p38α MAPK, exhibiting an IC50 value of 1.5 µM. This compound demonstrates significant efficacy in the prevention of mechanical allodynia in vivo, making it a valuable tool for research into pain mechanisms and inflammatory responses. Its specificity and potency render it suitable for investigating the role of p38α MAPK in various biological contexts, including neurobiology and chronic pain studies. -
p38α Inhibitor
P38α-IN-11 is a selective inhibitor of p38α, exhibiting a KD value of 586 nM. This compound is primarily utilized in research investigating cervical cancer, enabling studies on the modulation of p38α signaling pathways and their implications in tumorigenesis. Its inhibitory effects make it a valuable tool for elucidating the role of p38α in cancer biology. -
p38 Inhibitor
p38 Kinase Inhibitor 4 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), which plays a crucial role in mediating cellular responses to stress and inflammation. This compound demonstrates significant anti-inflammatory activity, making it valuable for research in inflammation-related diseases and cellular signaling pathways. It serves as an essential tool for studying p38 MAPK's role in such processes and evaluating potential therapeutic strategies. -
p38 MAPK Inhibitor
p38 MAPK-IN-9 is a selective inhibitor of p38α mitogen-activated protein kinase (MAPK), demonstrating an IC50 value of 9.6 nM. This compound exhibits potent anti-inflammatory activity, making it a valuable tool for research into inflammatory diseases, including rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD). Its oral bioavailability and high selectivity position p38 MAPK-IN-9 as an effective reagent for exploring the role of p38 MAPK in various biological pathways and therapeutic interventions. -
p38 MAPK Inhibitor
AZD 6703 is a selective inhibitor of p38α MAP kinase, targeting the MAPK pathway involved in inflammatory responses. It demonstrates significant anti-inflammatory activity, making it a valuable tool for investigating inflammatory diseases and related therapeutic interventions. Researchers can utilize AZD 6703 to explore p38 MAPK's role in various cellular processes and to develop strategies for modulating inflammation. -
p38 Inhibitor
L-167307 is a potent p38 kinase inhibitor that exhibits anti-inflammatory properties. It has been shown to significantly reduce secondary paw swelling in rat models of adjuvant-induced arthritis. This compound is valuable for research applications involving inflammation and pain pathways, facilitating the study of p38-mediated signaling in various disease models. -
PLK1/p38γ Inhibitor
PLK1/p38γ-IN-1 is a multitarget inhibitor that selectively targets PLK1 and p38γ kinases. This compound has demonstrated the ability to inhibit cell proliferation in human hepatocellular carcinoma and hepatoblastoma cell lines in vitro. PLK1/p38γ-IN-1 is valuable for research focused on cancer biology and the modulation of cell cycle pathways. -
p38 MAPK Inhibitor
Ganoderterpene A is a potent inhibitor of p38 MAPK, demonstrating significant anti-inflammatory and anti-apoptotic activity. It effectively attenuates LPS-induced inflammation and apoptosis by suppressing the MAPK and TLR-4/NF-κB signaling pathways in BV-2 cells. This compound is valuable for research applications focused on neuroinflammation and cellular stress responses. -
P38 MAPK Inhibitor
2-Stearoxyphenethyl phosphocholin is a potent inhibitor of p38 MAPK, a key regulator of inflammatory and stress response pathways. This compound demonstrates significant anticancer activity and may selectively interact with the lipid-binding pocket of p38 MAPK, influencing its function. Due to its broad-spectrum anti-tumor properties and lipid-modulating effects, it is applicable in cancer research and studies focused on metabolic regulation. -
p38α inhibitor
p38-α MAPK-IN-5 is a potent inhibitor of p38α MAPK, exhibiting competitive affinity with an IC50 of 0.1 nM against p38α, and 0.2 nM for p38β, while displaying reduced efficacy toward p38γ and p38δ. This compound demonstrates significant anti-inflammatory properties, making it a valuable tool for researching inflammatory pathways associated with conditions such as asthma and chronic obstructive pulmonary disease (COPD). Its specificity for p38α underscores its potential utility in studies aimed at elucidating the role of this kinase in inflammatory responses and related therapeutic interventions. -
p38 MAP Inhibitor
BIRB-1017 is a selective inhibitor of p38 MAP kinase, a key regulator in the inflammatory response. It demonstrates significant biological activity by modulating cytokine production and cellular signaling pathways associated with inflammation. This compound is suitable for use in research focused on understanding p38 signaling in various inflammatory diseases and therapeutic interventions. -
p38 MAP Kinase Inhibitor
p38 MAPK-IN-10 is a potent inhibitor of p38 MAP kinase, exhibiting an IC50 of 570 nM. This orally active compound shows promise in the study of chronic inflammatory diseases, including rheumatoid arthritis and Crohn’s disease. Its mechanism of action targets the p38 MAPK signaling pathway, making it a valuable tool for researchers investigating therapeutic approaches to modulate inflammation. -
p38α Inhibitor
R-130823 is a highly selective p38α inhibitor that exhibits an IC50 of 22 nM specifically against p38α, with minimal activity towards p38β (IC50 of 820 nM) and no significant interaction with p38γ or p38δ. This compound effectively downregulates cartilage degradation and inflammatory mediators, including the inhibition of MMP-13, MMP-1, and PGE2 release. R-130823 demonstrates therapeutic potential in reducing hind paw swelling, alleviating hyperalgesia, and impeding the progression of arthritis. It is particularly relevant for research studies focusing on osteoarthritis and rheumatoid arthritis. -
p38 Kinase Inhibitor
p38 Kinase Inhibitor 5 (AA6) selectively targets p38 MAP kinase, exhibiting a potent inhibitory effect with an IC50 of 403.57 nM. This compound is known for its significant anti-inflammatory activity, making it a valuable tool for research in inflammatory disease models and studies related to cytokine signaling pathways. Its role in modulating p38 kinase activity can provide insights into the mechanistic understanding of various pathological conditions. -
p38 MAP Kinase/Phosphodiesterase 4 Inhibitor
CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4, exhibiting potent anti-inflammatory and anti-allodynic effects. This compound significantly decreases the production of the proinflammatory cytokine IL-6 while elevating levels of the anti-inflammatory cytokine IL-10 in rat models. Additionally, CBS-3595 effectively mitigates paw edema in the Complete Freund’s adjuvant-induced arthritis model, making it a valuable tool for investigating potential therapies for autoimmune diseases. -
p38α Inhibitor
p38α inhibitor 7 is a potent inhibitor of the p38α mitogen-activated protein kinase, a key regulator of inflammation and stress responses. This compound demonstrates significant biological activity by effectively modulating the p38α pathway, making it applicable in studies exploring inflammatory diseases and neurological disorders. Its favorable pharmacokinetic properties enhance its potential for oral administration in therapeutic research. -
p38 MAP Inhibitor
AW-814141 is a selective and orally active inhibitor of p38 MAP kinase, demonstrating IC50 values of 100 nM for p38-α and 158 nM for p38-β isoforms. This compound effectively reduces TNF-α production induced by LPS and demonstrates a dose-dependent inhibition of paw edema in rat models. AW-814141 serves as a valuable tool in studying anti-inflammatory mechanisms and has potential applications in researching inflammatory diseases, including rheumatoid arthritis. -
p38αMAPK Inhibitor
MW108 hydrochloride is a selective inhibitor of p38α MAPK, with an affinity (Ki) of 114 nM. This compound demonstrates the ability to mitigate beta-amyloid-induced synaptic impairments and cognitive dysfunction, making it a valuable tool for studying neurodegenerative disorders. Its central nervous system penetration enhances its utility in research focused on Alzheimer's disease and related pathologies. -
p38α-MK2 Inhibitor
p38α-MK2-IN-1 is a potent inhibitor of the p38α-MK2 complex, demonstrating an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and promotes joint repair, making it a valuable tool for studies focused on inflammation and regenerative medicine. Researchers can employ p38α-MK2-IN-1 in various applications, including drug discovery and the exploration of signaling pathways related to inflammatory responses. -
p38 Kinase Inhibitor
p38 Kinase-IN-9 is a potent p38 kinase inhibitor characterized by an IC50 of less than 1 μM. This compound is valuable for investigating the role of p38 kinase in various diseases, particularly those related to inflammation. It serves as a useful tool for research applications aimed at understanding the mechanistic pathways of p38-mediated disorders. -
p38α Inhibitor
p38α-IN-9 is a potent p38α inhibitor that effectively suppresses the enzymatic activity of p38α with an IC50 value below 20 nM. This compound inhibits MK2T334 phosphorylation, resulting in the activation of Cdc25b and Cdc25c, while concurrently inactivating Wee1. The modulation of these pathways induces mitotic catastrophe, aneuploidy, and polyploidy, contributing to DNA damage. p38α-IN-9 is particularly relevant in studies of colorectal cancer metastasis. -
p38 MAPK Inhibitor
(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating IC50 values of 26 nM for p38 α and 102 nM for p38 β. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research applications focused on inflammatory signaling pathways and related disease models. Its specificity towards p38 MAPK allows for the exploration of its role in cellular processes and therapeutic interventions in conditions associated with p38 MAPK dysregulation. -
p38α Inhibitor
p38α inhibitor 3 is a selective p38α inhibitor that impedes myoblast differentiation. By targeting the p38 MAPK pathway, this compound plays a crucial role in modulating cellular responses associated with inflammation and stress. Its applications include studying muscle development and cellular signaling processes in various research contexts. -
p38 MAP Kinase Inhibitor
p38 MAP Kinase-IN-2 is a potent inhibitor of the p38 MAP Kinase pathway, primarily involved in cellular stress responses and inflammation. This compound demonstrates significant inhibitory activity, making it valuable for cancer research and the investigation of various inflammatory diseases. Its mechanism and efficacy provide a useful tool for studying the role of p38 MAP Kinase in cellular processes and therapeutic applications. -
p38 MAPK Inhibitor
RPR-200765A methanesulfonate is a potent inhibitor of p38 MAPK, demonstrating an IC50 of 0.050 μM. This compound selectively targets the p38 MAPK pathway while showing minimal activity against Lck, ERK, ZAP70, and SYK. RPR-200765A methanesulfonate effectively inhibits TNFα production, making it a valuable tool for investigating inflammatory diseases and related cellular processes. -
p38α MAP Kinase Inhibitor
BMS-626531 is a selective inhibitor of p38α MAP kinase, demonstrating potent activity against this important signaling pathway. This compound has been shown to effectively modulate cellular responses associated with inflammation and stress, making it a valuable tool in cancer research. Its ability to inhibit p38α MAP kinase renders it useful for investigating mechanisms of tumor progression and potential therapeutic applications in oncology. -
p38 MAPK Inhibitor
p38-α MAPK-IN-6 is a selective inhibitor of the p38α mitogen-activated protein kinase (MAPK). This compound modulates inflammatory responses by inhibiting the activation of p38 MAPK, a key regulator in cellular stress signaling pathways. It is useful in research applications focused on studying inflammatory diseases, neurodegeneration, and cancer biology. -
p38 MAPK Inhibitor
Macranthoin G is a selective inhibitor of p38 MAPK, a critical signaling pathway involved in stress responses. This compound demonstrates protective effects against cytotoxicity induced by amyloid-beta (Aβ) and hydrogen peroxide in neuronal cells by downregulating p38 MAPK activity. Macranthoin G is a valuable tool for research applications related to neurodegenerative diseases, particularly Alzheimer’s Disease. -
p38 MAPK Inhibitor
p38 MAPK-IN-8 is a potent and selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). It exhibits strong oral bioavailability, making it an ideal candidate for in vivo studies. This compound is valuable for investigating inflammatory responses, autoimmune disorders, and various cancer pathways, facilitating a deeper understanding of these complex biological processes. -
p38α MAPK/BChE Inhibitor
ARRY-371797 is a potent and orally bioavailable inhibitor of p38α MAPK and butyrylcholinesterase (BChE), demonstrating IC50 values of 12.0 µM for p38α MAPK and 0.13 µM for BChE, with minimal activity against human acetylcholinesterase (hAChE). This compound shows promise for research applications in Alzheimer’s disease, particularly in the context of neuroinflammation and cholinergic system modulation. -
p38 MAP Kinase Inhibitor
p38 MAPK-IN-7 is a selective inhibitor of p38 MAP kinase, exhibiting an IC50 value of 170 nM. This compound demonstrates potent inhibition of p38 MAPK activity, making it a valuable tool for investigating the role of this kinase in various inflammatory diseases, including rheumatoid arthritis and septic shock. Its oral bioavailability enhances its potential for in vivo studies aimed at understanding the therapeutic implications of p38 MAPK modulation. -
p38α Mitogen-Activated Protein Kinase Inhibitor
R 1487 is a highly selective inhibitor of the p38α mitogen-activated protein kinase. It demonstrates promising biological activity by effectively modulating inflammatory signaling pathways, making it a valuable tool in the study of rheumatoid arthritis and other inflammatory conditions. This compound enables researchers to delve into the mechanisms of p38α inhibition and its potential therapeutic applications in chronic inflammatory diseases. -
p38 Inhibitor
PS-166276 is a potent inhibitor of p38 mitogen-activated protein kinase (MAPK). With an IC50 of 28 nM against p38 kinase, it demonstrates significant inhibitory effects while maintaining lower cytotoxicity. This reagent is valuable for research applications focusing on inflammation, cell signaling, and related therapeutic pathways involving p38 MAPK modulation. -
MEK Inhibitor
PD-254552 is a potent inhibitor of MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase), playing a significant role in disrupting MAPK signaling pathways. This compound has demonstrated significant hepatotoxicity and gastrointestinal toxicity in murine models, providing valuable insights for researchers studying the side effects associated with MEK inhibition. Its properties make it a relevant candidate for investigations into cancer therapies and related pharmacological studies. -
p38α Inhibitor
p38α Inhibitor 4 is a selective allosteric inhibitor targeting the p38α MAPK pathway, demonstrated by an IC50 value of 1.2 μM. This compound exhibits specificity for p38α, showing no activity against p38β, p38γ, and p38δ. p38α Inhibitor 4 is valuable for research exploring inflammatory responses, cell signaling pathways, and related disorders where p38α activity plays a critical role. -
p38 MAPK Inhibitor
Anti-inflammatory agent 7 is a selective p38 MAPK inhibitor that modulates the NF-κB/MAPK signaling pathway to inhibit proinflammatory cytokine production. This reagent demonstrates significant anti-inflammatory activity in LPS-treated RAW 264.7 cells and in in vivo models, making it a valuable tool for studying inflammatory responses and developing therapeutic strategies for related diseases. -
p38 Alpha Kinase Inhibitor
CP-944629 is a potent inhibitor of p38 alpha kinase with an IC50 value of 3.2 μM. This compound effectively modulates the p38 MAPK signaling pathway, making it valuable in the study of chronic inflammatory diseases. Its ability to inhibit p38 alpha kinase may provide insights into therapeutic strategies for conditions driven by excessive inflammation. -
P38 MAPK Inhibitor
NJK14047 is a selective inhibitor of p38 MAPK, a key signaling pathway involved in inflammatory responses. This compound effectively inhibits the differentiation of naive T-cells into Th1 and Th17 cells, thus modulating immune responses. NJK14047 has demonstrated therapeutic potential in preclinical models, ameliorating collagen-induced rheumatoid arthritis and imiquimod-induced psoriasis in mice, making it a valuable tool for research into inflammatory diseases and immune regulation. -
p38 Inhibitor
p38-α MAPK-IN-10 is a potent inhibitor of p38α MAPK, exhibiting an IC50 value of 4 nM. This compound is utilized in research to investigate the role of p38α in inflammatory processes, cellular stress responses, and various pathological conditions. Its selective inhibition makes it an essential tool for studying signal transduction pathways and developing potential therapeutic strategies. -
p38 MAPK Inhibitor Negative Control
SB 202474 is a negative control compound designed for p38 MAPK inhibition studies. Unlike its active analog SB203580, SB 202474 does not inhibit p38 MAPK activity, making it an essential tool for validating experimental results in MAPK pathways. Additionally, it has been shown to suppress melanin synthesis induction, providing further applications in biochemical research related to pigment production. -
p38 Inhibitor
p38 Kinase Inhibitor 7 is a potent inhibitor of p38α with an IC50 value of 5.25 nM. This compound effectively reduces TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM. p38 Kinase Inhibitor 7 is valuable for research focused on inflammation and related signaling pathways, making it a useful tool in cytokine modulation studies. -
p38 MAPK Inhibitor
SB-204900 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). This compound exhibits significant inhibition of p38 MAPK phosphorylation, making it a valuable tool in the study of inflammatory signaling pathways. SB-204900 is primarily utilized in research focused on understanding the molecular mechanisms underlying inflammatory responses and developing potential therapeutic strategies for related conditions.
